Nichole Tucker

Managing Editor

Nichole Tucker is the Managing Editor of Blood Cancers Today. Tucker has spent over 11 years curating storytelling pieces in healthcare, public health, and life sciences. She holds a Master’s degree in International Media from University College Dublin and a bachelor’s degree in Mass Communications from Virginia State University.

Articles by Nichole Tucker

Tycel Phillips, MDAggressive B-Cell Lymphoma | July 18, 2025
Explore expert insights on bispecifics, CAR T-cell therapy, and emerging regimens for B-cell lymphomas.
Listen Now
Nichole TuckerTransplantation & Cellular Therapy | July 10, 2025
Hematology/oncology fellow Joseph Van Galen, MD, is investigating the mechanisms behind immune-related adverse events.
Nichole TuckerMyeloma | July 9, 2025
Next-gen BCL-2 inhibitors show promise in RRMM as venetoclax struggles with OS in phase 3 BELLINI study.
Nichole TuckerMyeloma | July 3, 2025
Linvoseltamab earns FDA nod for RRMM with 70% ORR, monthly dosing, and lower CRS than other bispecifics.
Nichole TuckerNon-Sponsored | July 3, 2025
Ruxolitinib shows durable benefit and long-term safety in steroid-refractory chronic GVHD, REACH3 finds.
Nichole TuckerAcute Myeloid Leukemia | June 30, 2025
Dr. Amir Fathi discusses oral regimens and future AML therapy trends in this Editor’s Special of The HemOnc Pulse.
Nichole TuckerFollicular Lymphoma | June 27, 2025
FDA approves tafasitamab plus R2 for relapsed FL, showing 57% reduced risk of progression in phase 3 inMIND trial.
Nichole TuckerMyelodysplastic Syndromes | June 28, 2025
Bexmarilimab shows promising responses in high-risk MDS, with up to 85% ORR in the BEXMAB phase 2 study.
Nichole TuckerMyelodysplastic Syndromes | June 26, 2025
Luspatercept shows longer survival and transfusion independence in ESA-naïve lower-risk MDS, COMMANDS trial.
Nichole TuckerPrint | June 24, 2025
Vinayak (Vinay) Prasad, MD, MPH, has been appointed director of the FDA Center for Biologic Evaluation and Research.
Ruben A. Mesa, MDMyeloproliferative Neoplasms | July 7, 2025
The phase 3 SURPASS-ET trial presented at ASCO evaluated ropeginterferon alfa-2b versus anagrelide for the treatment of ET.
Nichole TuckerMeeting News | June 24, 2025
Cilta-cel improves PFS and OS in len-refractory MM across subgroups, including high-risk cytogenetics, per CARTITUDE-4.
Nichole TuckerMyelodysplastic Syndromes | June 10, 2025
IME shows strong efficacy in LR-MDS, offering transfusion independence in heavily pretreated, ESA-ineligible patients.
Nichole TuckerAggressive B-Cell Lymphoma | June 1, 2025
EPCOR shows durable remission and survival at 2 years in R/R LBCL, with promising safety from fixed-duration treatment.
Nichole TuckerTransplantation & Cellular Therapy | May 29, 2025
Axi-cel shows durable response in high-risk LBCL frontline treatment with 80% progression-free at 3 years in ZUMA-12 trial.
Nichole TuckerAcute Myeloid Leukemia | May 27, 2025
Sankalp Arora, MBBS, a second-year fellow at MD Anderson, presented data on FLT3 inhibitors in AML at the HemOnc Pulse Live.
Nichole TuckerMyelodysplastic Syndromes | May 13, 2025
Julie Braish, MBBCh, a third-year fellow at MD Anderson, presented data on azacitidine and venetoclax in HR-MDS and CMML.
Nichole TuckerChronic Lymphocytic Leukemia | May 14, 2025
CLL treatment is evolving. Dr. Ryan Jacobs shares why decisions now weigh indefinite therapy vs. time-defined options.
Nichole TuckerAcute Lymphoblastic Leukemia | May 6, 2025
During The HemOnc Pulse Live! Nick Short, MD gave a presentation on unanswered questions in ALL.
Nichole TuckerMeeting News | May 1, 2025
Phase 1b data suggest that continuous low-dose lenalidomide improves the therapeutic index in patients RRMM.